Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025

  • Total Assets More Than Doubled: The Company reported total consolidated assets of $16.2 million, a 103% increase from $8.0 million in Q2 2024, driven by stronger affiliate equity positioning and improved asset allocation.
  • Shareholders’ Equity Increased: Shareholders’ equity rose to $9.5 million from  $8.0 million in the same period last year, reflecting disciplined strategic consolidation and improved capital structure.

Disciplined EPS Management Shows Downward Trend in Losses

ABVC reported a diluted loss per share of $(0.13) for the second quarter of 2025,  showing a significant improvement compared to the full-year diluted loss per share of  $(0.42) in 2024. The narrowing loss underscores the Company’s continued focus on streamlining operations, reducing non-core expenditures, and prioritizing high-value growth initiatives.

Strategic Land Acquisition in Asia to Support R&D and GMP Expansion

Following the close of Q2, ABVC completed the acquisition of farmland in Taiwan valued at approximately $3.3 million. Although this asset will be recognized in the  Company’s third-quarter balance sheet, the transaction was finalized in Q2 and will be disclosed as a subsequent event to its quarterly report.

The land will serve as a strategic base for botanical ingredient cultivation, modular R&D  facilities, and GMP-compliant pilot-scale manufacturing, supporting the Company’s long-term expansion plans in Asia. The Company believes the plans for this land will enhance vertical integration, reduce external supply dependency, and lay the foundation for operational efficiency and shareholder value creation.

$350K in Licensing Revenue Collected in July Boosts Q3 Outlook

In July 2025, ABVC received a total of $350,000 in licensing revenue from three licensing partners: $150,000 from AiBtl BioPharma, Inc., $100,000 from OncoX  BioPharma, Inc., and $100,000 from ForSeeCon Eye Corporation. These payments, that will be recognized in Q3 of 2025, highlight the continued execution of the Company’s monetization strategy and reinforce momentum in licensing-based revenue streams.

“Our second-quarter results reflect the strategic discipline we’ve applied across our business,” said Dr. Uttam Patil, ABVC's Chief Executive Officer. “From doubling our  asset base to acquiring physical infrastructure in Asia and securing non-dilutive licensing  revenue, we’re working to position ABVC for sustainable long-term growth while  creating tangible value for our shareholders.”

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford  University, University of California at San Francisco, and Cedars-Sinai Medical Center.  For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates,"  "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties,  many of which are beyond the Company's control, and cannot be predicted or quantified,  and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed.  Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv)  loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual  Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United  States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:
Uttam Patil
Email: uttam@ambrivis.com
4928-4786-9789, v. 2

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.